EU Regulatory Reforms Mean Many Orphan Drug Producers Won’t Benefit From Incentives
Executive Summary
The EU’s regulatory reform package if unchanged could make orphan drug development less attractive, warn industry representatives.
You may also be interested in...
EU Legislative Reform: Pan-EU Launch Requirement Will ‘Take Two To Tango’
Companies are already used to uncertainty and will be able to adapt to the new product launch requirement in the EU’s legislative overhaul for the pharmaceutical sector, according to a commission representative.
EU’s ‘Significant Benefit’ Metric For Orphan Drugs Still A Thorn In Industry’s Side
Ipsen’s Bylvay is one of six medicines that the European Medicines Agency has said should be stripped of their orphan drug designation over the last three years, leading the company to criticize the agency’s approach to “significant benefit” assessments.
EU Orphan Drug Law Reform Will See Innovation Drop By 12%, Industry Warns
The European Commission’s proposals to overhaul the EU pharma legislation, which will see some orphan drug incentives cut, would cause a “significant dip in innovation,” according to number crunching from pharma industry association EFPIA.